Retatrutide 10 mg in Europe | LIFE supplies Retatrutide 10 mg as a lyophilized research peptide with ≥99% purity and batch documentation. Orders are shipped from within the EU, with Economy, Standard Courier and Air Express options available depending on destination.

Available in two formats

Choose between a conventional lyophilized vial and a dual-chamber cartridge.

The cartridge keeps Retatrutide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.

3rd generation weight management peptide

Retatrutide 10 mg is a research-grade triple agonist peptide supplied in lyophilised form for laboratory use. It acts on GLP-1, GIP and glucagon receptors and has attracted strong interest in metabolic research, particularly in models of appetite regulation, body-weight change, glycaemic control and energy balance.

Retatrutide belongs to a newer class of investigational metabolic peptides designed to engage multiple receptor pathways simultaneously, rather than targeting GLP-1 alone. This makes it especially relevant in research focused on incretin biology, glucose homeostasis, energy expenditure and next-generation obesity models. Because of its broad receptor activity, Retatrutide is considered a step beyond traditional GLP-1 analogues, offering a new horizon for studies in obesity and related conditions. Compared to dual agonists such as Tirzepatide and single-pathway compounds like Semaglutide, Retatrutide represents a broader multi-pathway research model. For a detailed comparison of incretin-based compounds, see our GLP-1 metabolic research guide.

Looking to buy Retatrutide in Europe? LIFE Peptide supplies high-purity Retatrutide for laboratory research with reliable EU-wide shipping.

What is Retatrutide?

Retatrutide is an investigational triple agonist peptide developed to activate three key receptor systems involved in metabolic regulation:

GLP-1 receptor
GIP receptor
glucagon receptor

This receptor profile makes Retatrutide mechanistically broader than Semaglutide and Tirzepatide. Semaglutide primarily targets GLP-1, while Tirzepatide combines GLP-1 and GIP activity. Retatrutide adds a third component — glucagon receptor agonism — which is one of the reasons it has drawn so much attention in metabolic and obesity-related research. Retatrutide is described in the literature as an investigational triple-hormone receptor agonist with activity across all three pathways.

Why Retatrutide matters in metabolic research

Retatrutide is being studied because it combines incretin signalling with glucagon-receptor activity, creating a broader metabolic profile than standard GLP-1 analogues.

In the literature, Retatrutide has been investigated in relation to:

body-weight regulation and appetite signalling
glucose metabolism and glycaemic markers
energy expenditure and substrate utilisation
multi-pathway incretin research
next-generation obesity and metabolic-disease models

For researchers comparing newer metabolic peptides, Retatrutide is often discussed alongside Semaglutide and Tirzepatide because it extends beyond GLP-1/GIP into triple-pathway metabolic modulation. Reviews and overviews consistently describe it as a multi-receptor peptide being studied for obesity and metabolic control, with a receptor profile broader than earlier incretin agents.

How Retatrutide works

Retatrutide is designed to activate three receptor systems involved in metabolic control:

GLP-1 receptor activity

GLP-1 signalling is associated with appetite reduction, delayed gastric emptying and glucose-dependent insulin support. This is the pathway most researchers already know from compounds such as Semaglutide.

GIP receptor activity

GIP signalling is thought to influence insulin secretion, nutrient handling and adipose metabolism. In dual-agonist and triple-agonist research, it may contribute to a broader incretin response than GLP-1 alone.

Glucagon receptor activity

This is the major differentiator. Glucagon-receptor activation is being studied for its role in energy expenditure, hepatic metabolism and body-weight regulation, making Retatrutide mechanistically broader than both Semaglutide and Tirzepatide.

Together, these pathways make Retatrutide a useful model compound for research into multi-receptor metabolic signalling rather than single-pathway incretin activity alone. Eli Lilly’s own overview and recent review literature both describe Retatrutide as a once-weekly investigational triple agonist acting on GLP-1, GIP and glucagon receptors.

Published clinical findings on Retatrutide

Retatrutide has attracted unusual attention because human clinical studies have reported substantial effects on body weight, glycaemic markers and broader cardiometabolic parameters. In published phase 2 research in adults with obesity or overweight, investigational retatrutide produced dose-dependent weight reduction, with the highest-dose groups showing some of the strongest body-weight outcomes reported so far for an incretin-based agent.

More recently, Eli Lilly reported phase 3 obesity data from TRIUMPH-1, where participants on the 12 mg arm lost an average of 28.3% of body weight over 80 weeks, with a substantial share achieving at least 30% weight loss. Those results are not yet the same as an approved product label, but they materially strengthen Retatrutide’s position as one of the most closely watched next-generation metabolic peptides in development.

Retatrutide has also shown clinically meaningful effects in type 2 diabetes research. In Lilly’s phase 3 TRANSCEND-T2D-1 results, Retatrutide reduced HbA1c by roughly 1.7% to 2.0%, alongside substantial weight loss, reinforcing the idea that its triple-agonist profile may extend beyond appetite and body weight into broader metabolic control.

Study	Population	Main Findings
Phase 1	Healthy volunteers	Demonstrated acceptable safety profile and pharmacokinetic characteristics supporting once-weekly administration.
Phase 2 Obesity Trial	Adults with obesity or overweight	Mean weight reduction approached 24% after 48 weeks at the highest investigated dose, with improvements in waist circumference and several metabolic parameters.
Phase 2 Type 2 Diabetes Trial	Adults with type 2 diabetes	Significant reductions in HbA1c, body weight and fasting glucose compared with baseline and placebo.
Phase 3 TRIUMPH Program	Adults with obesity or overweight, including populations with type 2 diabetes and cardiovascular disease	Positive topline results have been reported from multiple Phase 3 trials. In TRIUMPH-1, the 12 mg group showed 28.3% mean weight reduction at 80 weeks; TRIUMPH-2 and TRIUMPH-3 subsequently reported substantial weight reduction in populations with type 2 diabetes and established cardiovascular disease.

Published safety and tolerability findings

Published clinical studies on investigational Retatrutide indicate that the most commonly reported adverse events are gastrointestinal, especially nausea, diarrhoea, vomiting and constipation. In the phase 2 obesity trial published in the New England Journal of Medicine, these events occurred more often with Retatrutide than with placebo, were generally dose-related, and were reported predominantly during the dose-escalation period. Most were described as mild to moderate in severity.

The phase 2 data also suggest that tolerability may be influenced by the starting dose and escalation schedule. Gastrointestinal adverse events were partly mitigated when escalation began from 2 mg rather than 4 mg, which is consistent with the broader incretin-drug class, where tolerability often improves with slower titration. Dose-dependent increases in heart rate were also reported, peaking during the trial and declining later.

As with other incretin-based agents, adverse events were one of the main reasons for treatment discontinuation in clinical trials, especially at higher doses. For that reason, Retatrutide’s clinical profile is usually discussed not only in terms of weight-loss efficacy, but also in terms of tolerability during escalation, GI event burden, and the balance between efficacy and dropout risk. This section summarises published findings on investigational Retatrutide, not instructions or expectations for use of this product.

Published dosing schedules used in Retatrutide research

Published clinical studies on investigational Retatrutide used once-weekly subcutaneous administration with stepwise dose escalation rather than fixed full-dose initiation. In the phase 2 obesity trial published in the New England Journal of Medicine, participants were assigned to several dose arms: 1 mg, 4 mg, 8 mg and 12 mg, with some higher-dose groups starting at a lower introductory dose before escalating. Specifically, the trial included 4 mg with an initial dose of 2 mg, 4 mg with an initial dose of 4 mg, 8 mg with an initial dose of 2 mg, 8 mg with an initial dose of 4 mg, and 12 mg with an initial dose of 2 mg, all administered once weekly for 48 weeks.

In practical terms, that means published Retatrutide research did not use a single universal schedule. The phase 2 program tested both slower escalation and faster escalation approaches to reach the same maintenance dose, which is one reason the study is useful not only for efficacy, but also for tolerability comparisons. For example, some 8 mg groups began at 2 mg and escalated upward, while others began at 4 mg before reaching the same target dose. The 12 mg arm also used 2 mg as the initial dose before escalation.

The type 2 diabetes phase 2 study used a similar logic. Participants received once-weekly Retatrutide at 0.5 mg, 4 mg, 8 mg, or 12 mg, with separate escalation and non-escalation arms in some groups — again highlighting that the published research focused heavily on dose-escalation strategy, not only on final dose.

Published study arm	Initial dose used in the trial	Target dose	Frequency	Study duration
Obesity phase 2	1 mg	1 mg	once weekly	48 weeks
Obesity phase 2	2 mg	4 mg	once weekly	48 weeks
Obesity phase 2	4 mg	4 mg	once weekly	48 weeks
Obesity phase 2	2 mg	8 mg	once weekly	48 weeks
Obesity phase 2	4 mg	8 mg	once weekly	48 weeks
Obesity phase 2	2 mg	12 mg	once weekly	48 weeks

These schedules are included as a summary of published research design and are not instructions for use of this product.

Why Retatrutide Is different

Most modern metabolic peptides target one or two biological pathways involved in appetite regulation. Semaglutide activates the GLP-1 receptor, primarily reducing appetite and slowing gastric emptying. Tirzepatide combines GLP-1 and GIP receptor activation, further improving glycemic control and body weight outcomes.

Retatrutide expands this concept by activating three receptors simultaneously: GLP-1, GIP and glucagon. While GLP-1 and GIP primarily influence appetite regulation and insulin signaling, glucagon receptor activity appears to increase energy expenditure in addition to reducing food intake.

This triple-agonist approach distinguishes Retatrutide from currently approved dual agonists and has produced some of the largest reductions in body weight reported in clinical development. Ongoing Phase 3 studies continue to evaluate its long-term efficacy and safety.

Retatrutide vs Semaglutide vs Tirzepatide

Researchers often compare these compounds because they sit on the same metabolic spectrum, but they are not interchangeable.

Retatrutide

Triple agonist: GLP-1 + GIP + glucagon
Broadest receptor profile of the three
Often discussed in relation to body-weight outcomes, appetite regulation and energy expenditure

Tirzepatide

Dual agonist: GLP-1 + GIP
Positioned between Semaglutide and Retatrutide in mechanism
Widely studied for glycaemic control and body-weight effects

For a detailed comparison of receptor activity, published clinical findings and research differences, read our Retatrutide vs Tirzepatide research comparison.

Semaglutide

Single agonist: GLP-1
Best-known and most established of the three
Common reference point for GLP-1 pathway research

For researchers building a metabolic peptide panel, Retatrutide is generally the most relevant when the goal is to explore triple-pathway signalling rather than standard GLP-1 activity alone.

Product characteristics

Purity: ≥ 99% (HPLC) with batch-specific COA
Appearance: white lyophilized powder
Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4731.33±1.0
Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(α-Me-Leu)-Leu-Asp-Lys-(diacid-C20-γ-Glu-(AEEA)-Lys)-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Application: laboratory and analytical research

Storage: unopened lyophilized vials are best stored refrigerated at 2–8°C, which is the storage method confirmed by our manufacturing partner and suitable for up to 24 months. Refrigeration is preferred because it minimizes unnecessary freeze–thaw cycles during routine handling. If substantially longer-term storage is required, unopened lyophilized vials may also be kept frozen. Once reconstituted, always store at 2–8°C and do not freeze.

Independent third-party verification

This batch has undergone additional third-party analytical verification through Janoshik Analytical
Batch: RT10-260410
Internal HPLC purity: 99.17%
Third-party verification: 99.57% independently confirmed high purity and identity consistency. View third-party verification.

Reconstitution and handling

Retatrutide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. It must be reconstituted with bacteriostatic water before use. GLP-1 class peptides are sometimes slow to dissolve and require very gentle reconstitution to avoid foaming or remaining slightly cloudy.

For other solvent selection, concentration planning and storage guidance, see the full Peptide Reconstitution Guide and Reconstitution Calculator

Selected research references

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023.
Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.
Katsi V et al. Retatrutide—A Game Changer in Obesity Pharmacotherapy. 2025 review article.

Frequently Asked Questions

What kind of peptide is Retatrutide?

Retatrutide is an investigational triple agonist peptide designed to activate GLP-1, GIP and glucagon receptors.

How is Retatrutide different from Semaglutide?

Semaglutide targets GLP-1 only, while Retatrutide combines GLP-1, GIP and glucagon receptor activity, giving it a broader metabolic signalling profile.

How is Retatrutide different from Tirzepatide?

Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor activity, which is one of the main reasons it has attracted attention in next-generation metabolic research.

What research areas is Retatrutide associated with?

Retatrutide has been studied in the literature in relation to body-weight outcomes, appetite regulation, glycaemic control, incretin signalling and energy metabolism.

Can Retatrutide be stored at room temperature?

Retatrutide powder is generally more stable before reconstitution than after it has been dissolved. For long-term laboratory storage, refrigeration is recommended according to the intended storage period.

How long can reconstituted Retatrutide be stored?

The stability of reconstituted Retatrutide depends on storage conditions and the diluent used. Laboratory practice generally recommends refrigerated storage and minimizing repeated warming and cooling cycles.

Can Retatrutide be frozen after reconstitution?

Repeated freeze-thaw cycles may accelerate peptide degradation. If freezing is required for laboratory research, aliquoting the solution before freezing is generally preferred.

Does Retatrutide dissolve easily?

Yes. Retatrutide typically dissolves readily in bacteriostatic water when handled gently. Vigorous shaking is generally unnecessary.

Should Retatrutide be shaken after adding diluent?

Gentle swirling is generally preferred over vigorous shaking to minimize foaming and unnecessary mechanical stress on the peptide solution.

Can Retatrutide be transported without refrigeration?

Yes. Our lyophilized Retatrutide is more tolerant of short periods at ambient temperature than reconstituted solution. Extended exposure to heat should be avoided whenever possible.

Why is Retatrutide considered a triple agonist?

Unlike GLP-1 receptor agonists alone, Retatrutide activates the GLP-1, GIP and glucagon receptors simultaneously, making it one of the first triple agonists to enter advanced clinical development.

What makes Retatrutide different from earlier GLP-1 peptides?

Retatrutide combines three complementary metabolic pathways into a single molecule. This multi-receptor approach has produced some of the largest weight-loss results reported in clinical studies to date.

Can I buy Retatrutide in Europe?

Yes, Retatrutide 10 mg is available from LIFE for laboratory research purposes. Orders are dispatched from within the EU, with delivery available to most European destinations. Each batch includes analytical documentation, with independent third-party testing available for selected batches.. Available shipping methods and delivery times are shown during checkout based on your destination.

Is this product intended for human use?

No. This product is supplied strictly for research use only and is not intended for human consumption or therapeutic use.

Related research context

Retatrutide is part of the GLP-1/GIP/glucagon triple-receptor agonist metabolic research class. For mechanistic comparison with single and dual agonists, see our GLP-1 metabolic research guide. For a detailed comparison of receptor activity, published clinical findings and research differences, read our Retatrutide vs Tirzepatide research comparison.

Browse all compounds in the Metabolic research category.

Researchers comparing multi-receptor activation may also examine:

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

agonist triplu

Amestec Cagrilintidă 5 mg + Retatrutidă 10 mg

Retatrutidă 10 mg